Modality
Radioligand
MOA
PD-1i
Target
LAG-3
Pathway
Wnt
PV
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Jan 2026
Phase 2Current
NCT08027384
2,092 pts·PV
2021-11→2026-01·Recruiting
2,092 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-053mo agoPh3 Readout· PV
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-01-05 · 3mo ago
PV
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08027384 | Phase 2/3 | PV | Recruiting | 2092 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| ZYM-2450 | Zymeworks | Phase 2 | GLP-1R | |
| STO-2663 | Stoke Ther | Approved | LAG-3 | |
| Nidarelsin | Uniqure | Phase 2/3 | RET |